November 20, 2026 · BMC women's health · DOI: 10.1186/s12905-026-04826-z

Long-term risk of second primary malignancies and symptomatic heart failure after pegylated liposomal doxorubicin versus conventional anthracycline-based chemotherapy in early-stage breast cancer survivors: a single-center experience.

Listen to this summary

This retrospective single-center study of 1,372 early-stage breast cancer patients asked whether pegylated liposomal doxorubicin (PLD) or conventional anthracyclines increase long-term risk of second primary malignancies (SPM) or symptomatic heart failure (HF) compared with no chemotherapy, and how their survival compares. Neither anthracycline regimen was associated with a significantly higher SPM or HF risk than the reference group, and after 1:4 cardinality matching, disease-free and overall survival did not differ between PLD and conventional anthracyclines. The small PLD cohort (51 patients) and few events, however, mean the findings cannot establish equivalence or definitive cardiac safety for PLD.

Yu-Ting Lee, Hsin-Yi Yang, Chi-Wen Tu, Yu-Chen Hsu, Min-Chieh Shieh, Cheng-Yen Lee, Chih-Chia Chang, Yuk-Wah Tsang, Yu-Wen Wang, Wei-Yu Wang, Chin-Ho Kuo, Ming-Yang Lee, Yin-Che Lu, Po-Yen Hsu, Michael W Y Chan

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play